Thyroid Hurthle cell carcinoma

This phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…

This study tests a drug called vudalimab in people with advanced anaplastic thyroid cancer or aggressive hurthle cell thyroid cancer that has spread. The drug helps the immune system attack cancer cells and may slow tumor growth. About 54 participants will receive the treatment t…

This phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…

This study looks at whether low-risk thyroid cancer patients need radioactive iodine treatment after having their thyroid removed. About 504 participants are randomly assigned to receive either a standard dose of radio-iodine or no radio-iodine at all. The goal is to see if skipp…

This phase 2 trial tests whether adding everolimus to sorafenib works better than sorafenib alone for people with advanced Hurthle cell thyroid cancer that no longer responds to radioactive iodine. The study includes 35 participants and measures how long the cancer stays under co…